The above results indicate that, although the overall evidence supports high IGF-I as a potential risk factor for prostate cancer, different study characteristics affect the effect size and consistency, and it is still necessary to combine sensitivity analysis and meta-regression to further explain the sources of heterogeneity. The gene discussed is IGF1; the disease is prostate carcinoma.